University of Iowa Health Care and UK-based Naitive Technologies have initiated a joint project to evaluate the diagnostic accuracy of OsteoSight, an FDA-designated breakthrough medical device. This device is designed to identify individuals at risk of low bone mineral density (BMD) using X-rays taken for other medical purposes. The project aims to enhance the early detection of osteoporosis, a condition affecting millions worldwide, and enable more timely interventions.
The primary objective of this project is to assess the accuracy of OsteoSight in identifying individuals at risk of low BMD compared to the current gold standard, the dual-energy X-ray absorptiometry scan (DEXA). The study will also investigate potential biases in the machine learning model and analyze reasons behind any instances of failed image processing. Up to 2,500 hip and pelvic X-ray images taken within 12 months of a DEXA scan will be utilized in the study.
“All efforts to diagnose and treat osteoporosis are important. Using technology to assess bone health from standard imaging may give us an opportunity to assess bone health earlier and intervene sooner—before the first fracture occurs,” said Lori Fitton, PhD, ARNP, a nurse practitioner with University of Iowa Health Care Orthopedics and Rehabilitation.
Osteoporosis presents a significant global health challenge, leading to 37 million fractures annually and costing health systems billions. It is often underdiagnosed and undertreated, with low screening uptake using DEXA. Many cases are diagnosed only after a fracture has occurred.
“We are thrilled to work with the team at University of Iowa Health Care on this project,” said John Connell, PhD, Principal Scientist at Naitive Technologies. “Our goal is to make early detection more accessible, ultimately improving patient outcomes and quality of life, and this study will help us ensure OsteoSight is as effective as possible.”
Naitive is a venture-capital-backed company focusing on population health innovation. It specializes in advanced digital technologies that enhance clinical capabilities in the detection, diagnosis, treatment, and management of chronic diseases. Naitive’s flagship technology, OsteoSight, integrates opportunistic assessments of bone mineral density into routine care pathways, addressing conditions such as osteopenia and osteoporosis.
